Five years ago, 12-year-old Alex Chiabai was one of the first boy in Canada to begin taking drisapersen, a promising drug that provided a glimmer of hope for Alex and […]
NEWPORT BEACH, Calif., June 8, 2017: CureDuchenne, a nonprofit dedicated to funding research and improving patient care for Duchenne muscular dystrophy, continues to support Dr. Kevin Flanigan from Nationwide Children’s […]
CureDuchenne is pleased to see that the FDA will hold an Advisory Committee Meeting (AdCom) for PTC Therapeutics’s drug Ataluren. We are hopeful for a full and fair review which […]
For Doug Penner, now 14, being part of the original drisapersen trial was a hopeful time; the drug enabled him to go on four-mile walks, climb stairs and even jump. […]
NEWPORT BEACH, Calif., May 31, 2017 – CD Access is a new nonprofit that provides patients access to drugs and therapies that are currently unavailable through clinical trial or prescription. […]
A webinar about “Newly Released Data on EMFLAZA vs Prednisone” presented by Dr. Craig McDonald, UC Davis Health, and hosted by CureDuchenne.
The 2017 American Society of Gene & Cell Therapy took place in Washington DC last week. The Duchenne community was treated to a wealth of data from projects utilizing gene […]
PTC is committed to getting patients onto EMFLAZA as quickly as possible, without interruption of therapy. For patients that are currently accessing EMFLAZA through Master Pharmacy importation from outside of […]
CureDuchenne firmly believes in working together to help any child with Duchenne muscular dystrophy find the support they need. Duchenne is a disorder which knows no cultural, economic, or social […]
